News and Trends 2 Aug 2022 Glycostem and medac sign deal on AML and MM product Glycostem Therapeutics B.V. and medac GmbH are to partner to commercialize Glycostem’s lead product, oNKord. oNKord is currently in a phase 1/2 clinical trial across 10 hospitals in five European countries. Glycostem is a Dutch clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf natural killer (NK) cells, and medac is an international pharmaceutical […] August 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Pleco Therapeutics expands into U.S. and names president Pleco Therapeutics BV, a biopharmaceutical company based in the Netherlands, has expanded, with the incorporation of a U.S. subsidiary, Pleco Therapeutics USA. Pleco Therapeutics, which develops novel treatments designed to detoxify the cancer promoting cellular micro-environment, also named Michael Stalhamer as the US subsidiary’s president and first employee. Stalhamer also serves on the global leadership […] July 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 First-ever Marketing Authorization Application for biosimilar targeting MS filed An international biotech, with headquarters in Amsterdam, has announced that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for its biosimilar product. Polpharma Biologics, which is dedicated to the development of biosimilars, announced on Friday (July 15) that natalizumab, similar to Tysabri, which treats multiple sclerosis, has been accepted as […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 Biotech food colorant startup Phytolon seals $14.5M in funding Phytolon, a developer of fermentation-based natural food colors, has secured $14.5 million in funding, led by DSM Venturing, to further progress its technology towards commercialization. Other participation came from Cibus Fund, Ginkgo Bioworks (in-kind investment in the form of Foundry services) and The Trendlines Agrifood Fund. Participation in the series A funding also includes some […] July 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2022 Cancer vaccine biotech CimCure raises €5M Dutch biotech company CimCure, which is focusing on the development of vaccine-based cancer immunotherapy, has raised more than €5M ($5.3M) in a financing seed round led by Dutch company Positron Ventures. CimCure, a spin-off of the Amsterdam UMC medical center, is set to use the funds to advance its vaccine up to phase 1-2 clinical […] June 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Mar 2022 Emerging Startups Take Aim at Lysosomal Storage Disorders Lysosomal storage disorders such as Niemann-Pick type C have proved difficult to tackle in the biotech industry. With recent funding rounds in the bag, Scenic Biotech and Maze Therapeutics strive to treat these conditions by activating protective genes. Lysosomal storage disorders are inherited conditions caused by mutations in metabolic enzymes found inside our cells, leading […] March 10, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2022 Fast Stroke Treatments in the Works with TargED’s €39M Series A Patients with sudden strokes and blood clotting conditions need faster and safer treatments. The Dutch company TargED Biopharmaceuticals has raised a €39M Series A round to fund the development of a fast-acting protein drug that could bridge this gap. Time is of the essence when treating acute ischemic stroke, a condition caused by a blood […] February 22, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 Sep 2021 The top 15 biotech companies to find in the Netherlands The Netherlands has established itself as a biotech and life sciences hub, possessing leading academic and research institutions and an excellent business infrastructure that makes it an attractive place for biotech companies to grow and thrive. In this article, we take a look at some of the top biotechs in the country. The Netherlands is […] September 2, 2021 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2021 Avantium and Carbios Capitalize on Growing Bioplastics Demand As the EU phases out a wide range of single-use plastics this year, investor interest is steadily increasing for adopting easily recyclable or bio-based plastics. In recent weeks, European biotechs Carbios and Avantium have taken big steps towards meeting rising demand. With millions of tons of plastic waste littering the ocean floors, truly solving our […] May 18, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2020 Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M Update (31/03/2020): AM-Pharma has raised an extra €47M on top of an existing €116M equity round to fund an upcoming phase III trial of a treatment for acute kidney injury. The money will help the Dutch biotech to prepare for its upcoming phase III trial of a protein drug for acute kidney injury, which is […] March 31, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Mar 2020 LSP Raises €528M in Largest European Life Sciences Investment Fund Healthcare investor Life Sciences Partners has closed the largest ever European venture capital fund dedicated to new medicines and technologies after raising €528M. LSP 6, the company’s largest private equity fund to date, attracted significantly more than the original €396M target from a diverse investor group that included governments and the EU-supported European Investment Fund. […] March 10, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2020 First-in-Class Drug For Inherited Metabolic Diseases Funded with €25M The Dutch startup Azafaros has raised €25M in Series A funding to push its drug for inherited lysosomal storage disorders into phase I. The round was led by the Dutch VC firm Forbion. Other investors participating in the round included the Swiss firm BioMedPartners and the Dutch company BioGeneration Ventures, which was Azafaros’ founding investor […] February 10, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email